Skip to main content
. Author manuscript; available in PMC: 2014 Sep 22.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008042. doi: 10.1002/14651858.CD008042.pub2

Comparison 4. Sumatriptan versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Participants with headache relief at 15 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  1.1 Subcutaneous 6 mg 2 258 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [1.77, 3.03]
2 Participants pain-free at 15 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  2.1 Subcutaneous 6 mg 2 258 Risk Ratio (M-H, Fixed, 95% CI) 2.77 [1.82, 4.21]
3 Participants using rescue medication 2 346 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.20, 0.47]
  3.1 Subcutaneous 6 mg 2 214 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.19, 0.53]
  3.2 Subcutaneous 12 mg 1 132 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.14, 0.58]
4 Participants with any adverse event 2 293 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [1.20, 2.70]
  4.1 Subcutaneous 6 mg 2 293 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [1.20, 2.70]